Trial Profile
Efficacy of Abatacept in Inflammatory Polyarthritis of Systemic Lupus Erythematosus (SLE)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Polyarthritis; Systemic lupus erythematosus
- Focus Therapeutic Use
- 01 Sep 2020 Status changed from recruiting to discontinued.
- 16 Apr 2019 Planned End Date changed from 1 Oct 2018 to 31 Dec 2019.
- 16 Apr 2019 Planned primary completion date changed from 1 Apr 2018 to 1 Aug 2019.